-VISIT OUR OTHER FORUMS- OB-GYN-L Ultrasound Ultrasound History Fibroid Forum Physicians-in-Training Tech Talk OBSTET-L (portuguese) OBGIN-L (spanish) Nursing

Re: GYN: Menostar From: Charlie Chambers (cchamber@gorge.net) Wed Sep 29 13:42:40 2004 Messages sorted by: [ date ][ thread ][ subject ][ author ] Next message: Garry E. Siegel, M.D.: "Re: GYN: Menostar" Previous message: RModugno@aol.com: "Re: GYN: Menostar" In reply to: RModugno@aol.com: "Re: GYN: Menostar" Next in thread: Garry E. Siegel, M.D.: "Re: GYN: Menostar" Reply: Garry E. Siegel, M.D.: "Re: GYN: Menostar" Two years doesn't seem long enough to feel confident about hyperplasia incidents. Plus, no meaningful fracture data. Would be a lot more helpful if these companies that are putting forth new meds for osteo to get some fracture data instead of quick BMD data. On Sep 29, 2004, at 11:24 AM, RModugno@aol.com wrote: > > In a message dated 9/29/04 12:14:35 AM Eastern Daylight Time, > zbnewton@bellsouth.net writes: > The limiting issue is the outlier who develops an endometrial > malignancy > while under such a regimen that has not been standardized  The > liability > issue will devastate the prescriber, regardless of benefit/risk > arguments. > > If the uterus is there with estrogen therapy, progesterone/progestin > additive on a standardized basis is obligatory. By today's standards, > p-therapy every 4 or 6 months for the individual who does develop > endometrial carcinoma will come back to bite you. > > Zach Newton > Z. B. Newton, III, M.D. > Atlanta/ Gyn > Zach, this comes from Berlex: >   > > "Menostar is a fundamentally new approach to post-menopausal > osteoporosis prevention. In a two-year clinical study, Menostar, with > a very low dose of estrogen, did not increase the risk of endometrial > hyperplasia among women with a uterus. Therefore, this patch does not > require a daily or monthly concomitant progestin," said Marie Foegh, > M.D., Vice President, Medical Affairs for Berlex Laboratories. "Until > now, we in the medical community never knew such small amounts of > estrogen could help maintain bone health. With Menostar, we can return > a woman's estrogen to the lowest level proven to prevent bone loss." > > I would suggest, therefore, that a 4 to 6 month progesterone > "challenge' is acceptable therapy. > > Robert Modugno Md MBA FACOG > > Marietta, GA > > http://www.novaobgyn.yourmd.com > >   > ************************************************************************ **** Charlie Chambers Hood River, OR USA cchamber@alumni.rice.edu "...not because I regard fishing as being so terribly important but because I suspect that so many of the other concerns of men are equally unimportant-and not nearly so much fun." John Voelker ************************************************************************ ***** Next message: Garry E. Siegel, M.D.: "Re: GYN: Menostar" Previous message: RModugno@aol.com: "Re: GYN: Menostar" In reply to: RModugno@aol.com: "Re: GYN: Menostar" Next in thread: Garry E. Siegel, M.D.: "Re: GYN: Menostar" Reply: Garry E. Siegel, M.D.: "Re: GYN: Menostar"

Return to

Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Jul 2 04:37:54 2008

The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.